Srinivasan AR. Treat to target in Crohn’s disease: A practical guide for clinicians. World J Gastroenterol 2024; 30(1): 50-69 [PMID: 38293329 DOI: 10.3748/wjg.v30.i1.50]
Corresponding Author of This Article
Ashish R Srinivasan, FRACP, MBBS, PhD, Consultant Physician-Scientist, Senior Lecturer, Department of Gastroenterology, Austin Health, No. 145 Studley Road, Heidelberg, Victoria, Melbourne 3083, Australia. ashish.srinivasan1@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 7, 2024; 30(1): 50-69 Published online Jan 7, 2024. doi: 10.3748/wjg.v30.i1.50
Treat to target in Crohn’s disease: A practical guide for clinicians
Ashish R Srinivasan
Ashish R Srinivasan, Department of Gastroenterology, Austin Health, Victoria, Melbourne 3083, Australia
Ashish R Srinivasan, Department of Gastroenterology, Eastern Health, Victoria, Melbourne 3128, Australia
Ashish R Srinivasan, Department of Medicine, University of Melbourne, Victoria, Melbourne 3052, Australia
Author contributions: Srinivasan AR conceptualised the study, reviewed the literature, and composed the manuscript.
Conflict-of-interest statement: Dr. Ashish Srinivasan has received speaker fees from Arrotex Pharmaceuticals and advisory fees from AstraZeneca and AbbVie.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ashish R Srinivasan, FRACP, MBBS, PhD, Consultant Physician-Scientist, Senior Lecturer, Department of Gastroenterology, Austin Health, No. 145 Studley Road, Heidelberg, Victoria, Melbourne 3083, Australia. ashish.srinivasan1@gmail.com
Received: October 10, 2023 Peer-review started: October 10, 2023 First decision: November 16, 2023 Revised: November 23, 2023 Accepted: December 21, 2023 Article in press: December 21, 2023 Published online: January 7, 2024 Processing time: 88 Days and 4.5 Hours
Core Tip
Core Tip: A treat-to-target (T2T) approach applies the principles of early intervention and tight disease control to optimise long-term outcomes in Crohn's disease. This is achieved through scheduled assessments of disease activity, wherein progress is measured against pre-defined treatment targets, to inform whether current therapy should be continued or modified. Despite its obvious promise, a lack of guidance to support the integration of a T2T approach into clinical practice has the potential to limit its widespread uptake. This review seeks to examine the current and emerging literature, to provide clinicians with practical guidance on how to incorporate the principles of T2T into routine clinical practice for the management of Crohn’s disease.
